Matthew Ronsheim is Chief of Pharma Sciences & MFG of Entasis Therapeutics Holdings Inc.. Currently has a direct ownership of 0 shares of ETTX, which is worth approximately $0. The most recent transaction as insider was on Jul 11, 2022, when has been sold 150,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Matthew Ronsheim Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 11 2022
SELL
Sale (or disposition) back to the issuer
-
150,000 Reduced 100.0%
0 Common Stock
Jul 07 2022
SELL
Disposition due to a tender of shares in a change of control transaction
$38,658 $2.2 p/Share
17,572 Reduced 100.0%
0 Common Stock
Jan 18 2022
BUY
Grant, award, or other acquisition
-
125,000 Added 42.72%
167,572 Common Stock
Nov 02 2021
SELL
Payment of exercise price or tax liability
$10,787 $2.94 p/Share
3,669 Reduced 7.93%
42,572 Common Stock
Oct 19 2021
SELL
Open market or private sale
$11,991 $3.19 p/Share
3,759 Reduced 7.52%
46,241 Common Stock
Oct 19 2021
BUY
Grant, award, or other acquisition
-
25,000 Added 33.33%
50,000 Common Stock
Jan 15 2021
BUY
Grant, award, or other acquisition
-
25,000 Added 50.0%
25,000 Common Stock

Also insider at

INVA
Innoviva, Inc. Healthcare
MR

Matthew Ronsheim

Chief of Pharma Sciences & MFG
Waltham, MA

Track Institutional and Insider Activities on ETTX

Follow Entasis Therapeutics Holdings Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ETTX shares.

Notify only if

Insider Trading

Get notified when an Entasis Therapeutics Holdings Inc. insider buys or sells ETTX shares.

Notify only if

News

Receive news related to Entasis Therapeutics Holdings Inc.

Track Activities on ETTX